

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 1 of 21
6.5 Population Modelling and Analysis	Version 1.0

Module 6 : Research

6.5 Population Modelling and Analysis

TABLE OF CONTENTS

1. SUMMARY	3
2. APPROACH	3
3. METHODOLOGY	3
3.1. Modeling approach	5
3.2. Data	6
3.2.1. Population-level data	6
3.2.2. Transition probabilities between nicotine-use states	6
3.3. Scenarios	7
3.3.1. Reference scenario	7
3.3.2. Conversion scenario	7
4. RESULTS	8
4.1. Expected product-use prevalences	8
4.2. Reduction in smoking-attributed deaths	9
5. DISCUSSION	10
6. REFERENCES	13
7. APPENDIX	15
7.1. (b) (4)	15
7.1.1. (b) (4)	16
7.2. (b) (4)	16
7.2.1. (b) (4)	16
7.2.2. (b) (4)	18

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 2 of 21
6.5 Population Modelling and Analysis	Version 1.0

7.2.3.	(b) (4)	19
7.3.	(b) (4)	21
7.3.1.	(b) (4)	21

LIST OF FIGURES

Figure 1.	(b) (4)	5
Figure 2.	(b) (4)	8
Figure 3.	(b) (4)	9
Figure 4.	(b) (4)	10
Figure 5.	(b) (4)	11
Figure 6.	(b) (4)	12

LIST OF TABLES

Table 1.	(b) (4)	17
Table 2.	(b) (4)	19
Table 3.	(b) (4)	20

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 3 of 21
6.5 Population Modelling and Analysis	Version 1.0

1. SUMMARY

Population modeling shows that the introduction of *IQOS* products will contribute to the reduction of smoking-related harm by offering adult smokers a less risky alternative. We evaluated the public health impact of *IQOS* products on smoking-attributed deaths between ages 30-79 due to four major smoking-related diseases: (i) lung cancer, (ii) chronic obstructive pulmonary disease, (iii) ischaemic heart disease and (iv) stroke between 2024 and 2080.

Our findings indicate that *IQOS* products will prevent about 50,000 smoking-related deaths for each percentage point of population prevalence that it reaches in 10 years after its introduction. For example, if the population prevalence of *IQOS* grows to 5% and stays steady until 2080, it leads to the reduction of 225,000 smoking-attributed deaths and 2.2 millions of years life saved (YLS).

2. APPROACH



3. METHODOLOGY



¹ See *IQOS* 2.4 MRTPA submitted on 5 Dec 2016, Section 7.4 Executive Summary: Population Health Impact Model studies and Appendix Report PHIM (Population Health Impact Model) System, Simulation and Sensitivity Analysis Report, Version 1.1, August 2016.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 4 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 5 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

3.1. Modeling approach

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 6 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

3.2. Data

3.2.1. Population-level data

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 7 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

3.3. Scenarios

(b) (4)

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 8 of 21
6.5 Population Modelling and Analysis	Version 1.0

4. RESULTS

(b) (4)

4.1. Expected product-use prevalences

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 9 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

4.2. Reduction in smoking-attributed deaths

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 10 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

5. DISCUSSION

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 11 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 12 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 13 of 21
6.5 Population Modelling and Analysis	Version 1.0

6. REFERENCES

- Boakye E, Osuji N, Erhabor J, Obisesan O, Osei AD, Mirbolouk M, Stokes AC, Dzaye O, El Shahawy O, Hirsch GA, Benjamin EJ. Assessment of patterns in e-cigarette use among adults in the US, 2017-2020. JAMA Network Open. 2022 Jul 1;5(7):e2223266-.
- Brouwer AF, Jeon J, Hirschtick JL, Jimenez-Mendoza E, Mistry R, Bondarenko IV, Land SR, Holford TR, Levy DT, Taylor JM, Fleischer NL. Transitions between cigarette, ENDS and dual use in adults in the PATH study (waves 1–4): multistate transition modelling accounting for complex survey design. Tobacco Control. 2022 May 1;31(3):424-31.
- Djurdjevic S, Lee PN, Weitkunat R, Sponsiello-Wang Z, Lüdicke F, Baker G. Modeling the population health impact of introducing a modified risk tobacco product into the US market. Healthcare 2018 May 16 (Vol. 6, No. 2, p. 47). MDPI.
- Djurdjevic S, Pecze L, Weitkunat R, Luedicke F, Fry J, Lee P. Using data on snus use in Sweden to compare different modelling approaches to estimate the population health impact of introducing a smoke-free tobacco product. BMC public health. 2019 Dec;19(1):1-3.
- Gardner JW, Sanborn JS. Years of potential life lost (YPLL)—what does it measure?. Epidemiology. 1990 Jul 1:322-9.
- Lee PN, Djurdjevic S, Weitkunat R, Baker G. Estimating the population health impact of introducing a reduced-risk tobacco product into Japan. The effect of differing assumptions, and some comparisons with the U.S. Regul Toxicol Pharmacol. 2018 Dec;100:92-104. doi: 10.1016/j.yrtph.2018.10.010. Epub 2018 Oct 24. PMID: 30367904.
- Lee PN, Hamling J, Fry J, Forey B. Using the negative exponential model to describe changes in risk of smoking-related diseases following changes in exposure to tobacco. Advances in Epidemiology. 2015.
- Lee PN, Fry JS, Forey BA. Trends in lung cancer, chronic obstructive lung disease, and emphysema death rates for England and Wales 1941-85 and their relation to trends in cigarette smoking. Thorax. 1990 Sep 1;45(9):657-65.
- Lee PN, Fry JS, Hamling JF, Sponsiello-Wang Z, Baker G, Weitkunat R. Estimating the effect of differing assumptions on the population health impact of introducing a Reduced Risk Tobacco Product in the USA. Regulatory Toxicology and Pharmacology. 2017 Aug 1;88:192-213.
- Lee PN, Abrams D, Bachand A, Baker G, Black R, Camacho O, Curtin G, Djurdjevic S, Hill A, Mendez D, Muhammad-Kah RS. Estimating the population health impact of recently introduced modified risk tobacco products: a comparison of different approaches. Nicotine and Tobacco Research. 2021 Mar;23(3):426-37.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 14 of 21
6.5 Population Modelling and Analysis	Version 1.0

Lee PN, Fry JS, Gilliland S, Campbell P, Joyce AR. Estimating the reduction in US mortality if cigarettes were largely replaced by e-cigarettes. *Archives of toxicology*. 2022 Jan;96(1):167-76.

Martin F, Vuillaume G, Baker G, Sponsiello-Wang Z, Ricci PF, Lüdicke F, Weitkunat R. Quantifying the risk-reduction potential of new Modified Risk Tobacco Products. *Regulatory toxicology and pharmacology*. 2018 Feb 1;92:358-69.

Mayer M, Reyes-Guzman C, Grana R, Choi K, Freedman ND. Demographic characteristics, cigarette smoking, and e-cigarette use among US adults. *JAMA Network Open*. 2020 Oct 1;3(10):e2020694-.

Osmond C, Gardner MJ. Age, period and cohort models applied to cancer mortality rates. *Statistics in Medicine*. 1982a;1(3):245-59.

Osmond C, Gardner MJ, Acheson ED. Analysis of trends in cancer mortality in England and Wales during 1951-80 separating changes associated with period of birth and period of death. *Br Med J (Clin Res Ed)*. 1982b Apr 3;284(6321):1005-8.

Rytsar R, Djurdjevic S, Nussbaum AK, Kaul A, Bennewitz E, Lee PN, Fry JS. Estimated Public Health Gains From German Smokers Switching to Reduced-Risk Alternatives: Results From Population Health Impact Modelling. *Contributions to Tobacco & Nicotine Research*. 2022a Mar 1;31(1):35-51.

Rytsar R, Djurdjevic S, Nussbaum AK, Kaul A, Bennewitz E, Lee PN, Fry JS. Estimated Public Health Gains From Smokers in Germany Switching to Reduced-Risk Alternatives: Results From Population Health Impact Modelling by Socioeconomic Group. *Contributions to Tobacco & Nicotine Research*. 2022b Mar 1;31(1):52-67.

Sutanto, Edward, Connor Miller, Danielle M. Smith, Ron Borland, Andrew Hyland, K. Michael Cummings, Anne CK Quah et al. Concurrent daily and Non-Daily use of heated tobacco products with Combustible cigarettes: findings from the 2018 ITC Japan survey. *International Journal of Environmental Research and Public Health*. 2020 17(6): 2098.

Weitkunat R, Lee PN, Baker G, Sponsiello-Wang Z, Ladd AM, Lüdicke F. A novel approach to assess the population health impact of introducing a modified risk tobacco product. *Regulatory Toxicology and Pharmacology*. 2015 Jun 1;72(1):87-93.

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 15 of 21
6.5 Population Modelling and Analysis	Version 1.0

7. APPENDIX

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 16 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 17 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 18 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 19 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 20 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.

Philip Morris Products S.A.	Confidential
Renewal of MR0000133, MR0000192, and MR0000059-MR0000061	Page 21 of 21
6.5 Population Modelling and Analysis	Version 1.0

(b) (4)

Confidentiality Statement

Data and information contained in this document are considered to constitute trade secrets and confidential commercial information, and the legal protections provided to such trade secrets and confidential information are hereby claimed under the applicable provisions of United States law. No part of this document may be publicly disclosed without the written consent of Philip Morris Products S.A.
